BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors

Haanen J, Mackensen A, Koenecke C, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, Borchmann P, Wiegert E, Schulz C, Rengstl B, Preussner L, Tuereci O, Sahin U (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S1392-S1392

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2021.10.216

Authors with CRIS profile

Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Antoni van Leeuwenhoek NL Netherlands (NL) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Universitätsklinikum Regensburg DE Germany (DE) Universitätsklinikum Köln DE Germany (DE) BioNTech / Biopharmaceutical New Technologies DE Germany (DE) Bexon Clinical Consulting US United States (USA) (US)

How to cite

APA:

Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E.,... Sahin, U. (2021). BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors. In ANNALS OF ONCOLOGY (pp. S1392-S1392). AMSTERDAM: ELSEVIER.

MLA:

Haanen, J., et al. "BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S1392-S1392.

BibTeX: Download